Business Context and Reporting Period
This Form 8-K reports on the annual meeting of stockholders for Proteon Therapeutics, Inc. held on June 9, 2016. The filing covers the submission of matters to a vote of security holders, specifically the election of directors and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
No material financial changes are reported in this filing. The document details the outcome of shareholder votes rather than operational or financial shifts compared to prior periods.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, risks, contingencies, or unusual items. The primary content is the tabulation of votes for the election of directors and the ratification of Ernst and Young LLP as the independent auditor for the fiscal year ending December 31, 2016.
Important Facts for Investors
- Meeting Date: The annual meeting occurred on June 9, 2016.
- Director Election: Stockholders elected all nominees, including Hubert Birner, Ph.D., and Stuart A. Kingsley.
- Auditor Ratification: Stockholders ratified the appointment of Ernst and Young LLP as the independent registered public accounting firm.
- Voting Results: Proposal 1 (Directors) received significant support with over 12.4 million votes for Hubert Birner and over 12.7 million for Stuart Kingsley. Proposal 2 (Auditor) received 13,585,449 votes in favor.
- Financial Data: No financial metrics are disclosed in this specific 8-K filing.